Primary headache with onset in childhood and adolescence: natural history and prognostic factors in a Portuguese population. [PDF]
Rev Neurol, 2023 da Silva Cardoso J +5 more
europepmc +1 more source
Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one. [PDF]
Rev Neurol, 2023 Fresán-Restituto D +3 more
europepmc +1 more source
[Episodic ataxia type 2: a clinical, genetic and radiological study of 10 patients]. [PDF]
Rev Neurol, 2023 Alcalá-Torres J +4 more
europepmc +1 more source
Acta Neurológica Colombiana, 2015 Introducción: La migraña es la cefalea primaria de mayor impacto en la población general; de acuerdo con la información local se calcula que al menos 3 millones de personas en Colombia padecen esta condición, conduciendo esta entidad a alta carga y ...
Joe Muñoz +12 more
doaj
[Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?] [PDF]
Rev Neurol, 2022 López-Moreno Y +3 more
europepmc +1 more source
[Comparison of tiapride and topiramate in the prophylactic treatment of chronic migraine: a randomised, double-blind, pilot study]. [PDF]
Rev Neurol, 2022 Juica-Avello S +10 more
europepmc +1 more source
Comorbidity between hypothyroidism and headache disorders in a Mexican population. [PDF]
Rev Neurol, 2022 Fernández-Garza LE, Marfil A.
europepmc +1 more source
[Clinical experience with erenumab during the first year of treatment]. [PDF]
Rev Neurol, 2022 Caso-González A +5 more
europepmc +1 more source
[Medication Review with Follow-up Service provided by the Community Pharmacy as a care practice for the optimization of pharmacotherapy in patient with urticaria and pruritus]. [PDF]
Farm Comunitarios, 2023 Pérez Rodríguez RO, Barreto Corujo NJ.
europepmc +1 more source
[CefaleApp: A Mobile Application for Migraine Diagnosis in Primary Health Care]. [PDF]
Rev NeurolGarcía-Estévez DA +2 more
europepmc +1 more source